Belimumab With Rituximab for Primary Membranous Nephropathy — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(20 sites)
United States
University of Alabama at Birmingham School of Medicine: Division of Nephrology, Birmingham, Alabama University of Arkansas, Little Rock, Arkansas University of California San Francisco, San Francisco, California Stanford University School of Medicine: Division of Nephrology, Stanford, California The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and Hypertension, Torrance, California University of Colorado, Aurora, Colorado Mayo Clinic Jacksonville: Department of Nephrology and Hypertension, Jacksonville, Florida University of Miami Miller School of Medicine, Div of Nephrology, Miami, Florida Johns Hopkins, Baltimore, Maryland National Institutes of Health Clinical Center, Bethesda, Maryland University of Michigan, Ann Arbor, Michigan University of Minnesota Health Clinical Research Unit, Minneapolis, Minnesota Washington University in St. Louis, St Louis, Missouri University of Nebraska, Omaha, Nebraska Columbia University Medical Center: Division of Nephrology, New York, New York University of North Carolina School of Medicine: Division of Nephrology and Hypertension, Kidney Center, Chapel Hill, North Carolina Cleveland Clinic, Cleveland, Ohio Ohio State University Wexner Medical Center: Division of Nephrology, Columbus, Ohio University of Pennsylvania: Department of Medicine: Renal-Electrolyte and Hypertension Division, Philadelphia, Pennsylvania Providence Medical Research Center, Providence Health Care: Nephrology, Spokane, Washington Age range
18 Years – 75 Years
Last updated February 2026